NeoGenomics (NEO) to Release Quarterly Earnings on Monday

NeoGenomics (NASDAQ:NEO) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, July 29th. Analysts expect the company to announce earnings of $0.00 per share for the quarter. NeoGenomics has set its FY 2024 guidance at 0.000-0.040 EPS.Parties interested in listening to the company’s conference call can do so using this link.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, April 30th. The medical research company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). NeoGenomics had a negative return on equity of 3.54% and a negative net margin of 13.79%. The firm had revenue of $156.24 million for the quarter, compared to analysts’ expectations of $149.82 million. On average, analysts expect NeoGenomics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeoGenomics Price Performance

Shares of NEO stock opened at $14.88 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.48 and a quick ratio of 7.22. The firm’s 50-day moving average is $13.93 and its two-hundred day moving average is $14.69. NeoGenomics has a 12 month low of $11.03 and a 12 month high of $21.22. The company has a market capitalization of $1.90 billion, a PE ratio of -22.55 and a beta of 1.19.

Wall Street Analyst Weigh In

A number of brokerages have commented on NEO. Needham & Company LLC reduced their target price on shares of NeoGenomics from $24.00 to $19.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. BTIG Research reduced their target price on shares of NeoGenomics from $23.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. Benchmark reaffirmed a “buy” rating and set a $18.00 target price on shares of NeoGenomics in a research note on Wednesday, May 1st. TD Cowen reduced their target price on shares of NeoGenomics from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Finally, Craig Hallum initiated coverage on shares of NeoGenomics in a research note on Wednesday, May 1st. They issued a “buy” rating and a $26.00 price target on the stock. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, NeoGenomics has a consensus rating of “Moderate Buy” and a consensus target price of $19.78.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.